Inflammatory Biomarkers and Clinical Outcomes in Hospitalized Hemodialysis Patients with COVID-19: A Retrospective...

Background/Objectives: Maintenance hemodialysis patients are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to evaluate clinical outcomes and identify admission laboratory biomarkers associated with in-hospital mortality in hospitalized hemodialysis patients with coronavirus disease 2019 (COVID-19). Methods: We conducted a retrospective observational study including 130 adult hemodialysis patients with confirmed SARS-CoV-2 infection. Clinical characteristics and admission laboratory parameters were analyzed in relation to in-hospital outcomes using comparative, multivariable logistic regression, and receiver operating characteristic (ROC) curve analyses. Results: The overall in-hospital mortality rate was 34.6%. The median age of the cohort was 66 years, with 64.6% male patients. Non-survivors showed significantly higher levels of inflammatory and tissue-injury markers, including C-reactive protein (CRP) (p < 0.001) and lactate dehydrogenase (LDH) (p < 0.001), together with lower serum albumin (p < 0.001), platelet count (p < 0.001), and lymphocyte levels (p = 0.03). In multivariable analysis, cardiovascular disease, respiratory disease, dyspnea, and ambulatory origin were independently associated with mortality. ROC analysis identified platelet count as the best individual predictor (area under the curve [AUC] = 0.767). An exploratory composite risk score demonstrated excellent discriminative performance (AUC = 0.902). Conclusions: Admission inflammatory and hematological biomarkers are strongly associated with adverse outcomes in hospitalized hemodialysis patients with COVID-19. The integration of clinical and laboratory parameters into a composite risk score may improve early risk stratification and support clinical decision-making in this high-risk population.